Hsp74/14‐3‐3σ Complex Mediates Centrosome Amplification by High Glucose, Insulin, and Palmitic Acid

Abstract

It has been reported recently that type 2 diabetes promotes centrosome amplification via 14-3-3σ /ROCK1 complex. In the present study, 14-3-3σ interacting proteins are characterized and their roles in the centrosome amplification by high glucose, insulin, and palmitic acid are investigated. Co-immunoprecipitation in combination with MS analysis identified 134 proteins that interact with 14-3-3σ , which include heat shock 70 kDa protein 4 (Hsp74). Gene ontology analyses reveal that many of them are enriched in binding activity. Kyoto Encyclopedia of Genes and Genomes analysis shows that the top three enriched pathways are ribosome, carbon metabolism, and biosynthesis of amino acids. Molecular and functional investigations show that the high glucose, insulin, and palmitic acid increase the expression and binding of 14-3-3σ and Hsp74 as well as centrosome amplification, all of which are inhibited by knockdown of 14-3-3σ or Hsp74. Moreover, molecular docking analysis shows that the interaction between the 14-3-3σ and the Hsp74 is mainly through hydrophobic contacts and a lesser degree ionic interactions and hydrogen bond by different amino acids residues. In conclusion, the results suggest that the experimental treatment triggers centrosome amplification via upregulations of expression and binding of 14-3-3σ and Hsp74.

Integrative Pathway Analysis of SNP and Metabolite Data Using a Hierarchical Structural Component Model

“…In addition, both HisCoM-SM methods identified the same pathway with the second-highest absolute coefficient value and the lowest q-value. This pathway is the biosynthesis of amino acids (map 01230) and has also been reported to be associated with T2D in previous studies ( Aichler et al, 2017 ; Lu et al, 2019 ). These results demonstrate that HisCoM-SM(single) and HisCoM-SM(GBLUP) can yield consistent results and identify pathways associated with T2D.…”

Drug Resistance and Novel Therapies in Cancers

“…Two research articles were related to melanoma [ 2 , 3 ]. One article was focused on targeting MAPK and the p53 pathway simultaneously to treat cutaneous melanoma [ 2 ].…”

“…Two research articles were related to melanoma [ 2 , 3 ]. One article was focused on targeting MAPK and the p53 pathway simultaneously to treat cutaneous melanoma [ 2 ]. This research revealed that ATM-dependent DUSP6 modulation of p53 is involved in synergistic targeting of MAPK and the p53 pathway by MEK inhibitor trametinib and MDM2 inhibitor nutlin-3/RG7388/HDM201 in cutaneous melanoma.…”